Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
• Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
• Assess the latest clinical evidence regarding the treatment of patients with ILD.

Activity Description

Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.

Agenda

Introduction
Steven D. Nathan, MD

Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis and Classification
Lisa H. Lancaster, MD

Long-Term and Real-World Studies in IPF – What Can We Learn?
Robert J. Kaner, MD

Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD

Activity Chair

Steven D. Nathan, MD
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA

Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech

Faculty

Robert J. Kaner, MD
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY

Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray

Lisa H. Lancaster, MD
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with interstitial lung disease (ILD).

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
• Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
• Assess the latest clinical evidence regarding the treatment of patients with ILD.

Activity Description

Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (e.g., asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational series including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.

Agenda

Introduction
Steven D. Nathan, MD

Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis and Classification
Lisa H. Lancaster, MD

Long-Term and Real-World Studies in IPF – What Can We Learn?
Robert J. Kaner, MD

Clinical Cases
Lisa H. Lancaster, MD, and Robert J. Kaner, MD

Activity Chair

Steven D. Nathan, MD
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA

Disclosures:
Consulting Fee: Altavant, Bellerophon, Boehringer Ingelheim, Galapagos, Roche/Genentech, United Therapeutics
Speakers Bureau: Boehringer Ingelheim, Roche/Genentech

Faculty

Robert J. Kaner, MD
Associate Professor of Clinical Medicine
Associate Professor of Genetic Medicine
Weill Cornell Medicine
New York, NY

Disclosures:
Consulting Fee: Boehringer Ingelheim, Galapagos, Genentech, Pliant, PureTech, United Therapeutics
Speakers Bureau: Genentech
Contracted Research: Bellerophon, Boehringer Ingelheim, Respivant, Toray

Lisa H. Lancaster, MD
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures:
Spouse: Medtronic
Consulting Fee: AstraZeneca, DevPro Biopharma, Galapagos, Genentech, United Therapeutics, Veracyte
Speakers Bureau: Boehringer Ingelheim, Genentech
Contracted Research: Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, FibroGen, Galapagos, Galecto, Novartis, Pliant, Respivant

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure:
No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure:
No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.58 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 21034784. This activity was planned in accordance with AANP Accreditation Standards and Policies.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Genentech, Inc. and Veracyte, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with nontuberculous mycobacterial lung disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to identify patients with nontuberculous mycobacterial lung disease (NTM-LD) using knowledge of the pathophysiology; environmental factors; underlying conditions (eg, bronchiectasis); and risk factors.

Activity Description

In this Curbside Consult, Drs. David Griffith and Kevin Winthrop discuss the case of a 50-year-old woman with rheumatoid arthritis and recent increase in cough. Samples taken during bronchoscopy are positive for both Mycobacterium avium and Mycobacterium abscessus, posing diagnostic and treatment challenges.

Statement of Educational Need

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM infection, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence and guidelines.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hour(s) of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-003-H01-P, effective 03/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25AAPA Category 1 CME Credit(s). Approval is valid from 3/31/2021 to 3/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202341.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with nontuberculous mycobacterial lung disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to identify patients with nontuberculous mycobacterial lung disease (NTM-LD) using knowledge of the pathophysiology; environmental factors; underlying conditions (eg, bronchiectasis); and risk factors.

Activity Description

In this Curbside Consult, Drs. David Griffith and Kevin Winthrop discuss the case of a 50-year-old woman with rheumatoid arthritis and recent increase in cough. Samples taken during bronchoscopy are positive for both Mycobacterium avium and Mycobacterium abscessus, posing diagnostic and treatment challenges.

Statement of Educational Need

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM infection, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence and guidelines.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hour(s) of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-003-H01-P, effective 03/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25AAPA Category 1 CME Credit(s). Approval is valid from 3/31/2021 to 3/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202341.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with nontuberculous mycobacterial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Identify patients with nontuberculous mycobacterial lung disease (NTM-LD) using knowledge of the pathophysiology; environmental factors; underlying conditions (eg, bronchiectasis); and risk factors.
• Review the newly updated guideline recommendations for the diagnosis and treatment of NTM-LD.

Activity Description

In this Curbside Consult, Drs. David Griffith and Charles Daley discuss workup, management, and follow-up of NTM lung disease in a 60-year-old woman presenting with cough, fatigue, mild dyspnea, and weight loss.

Statement of Educational Need

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM infection, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence and guidelines.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hour(s) of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-004-H01-P, effective 03/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25AAPA Category 1 CME Credit(s). Approval is valid from 3/31/2021 to 3/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202343.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with nontuberculous mycobacterial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Identify patients with nontuberculous mycobacterial lung disease (NTM-LD) using knowledge of the pathophysiology; environmental factors; underlying conditions (eg, bronchiectasis); and risk factors.
• Review the newly updated guideline recommendations for the diagnosis and treatment of NTM-LD.

Activity Description

In this Curbside Consult, Drs. David Griffith and Charles Daley discuss workup, management, and follow-up of NTM lung disease in a 60-year-old woman presenting with cough, fatigue, mild dyspnea, and weight loss.

Statement of Educational Need

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM infection, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence and guidelines.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hour(s) of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-004-H01-P, effective 03/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25AAPA Category 1 CME Credit(s). Approval is valid from 3/31/2021 to 3/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202343.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Jointly Provided By

Jointly provided by Postgraduate institute for Medicine and RMEI Medical Education, LLC.

Target Audience

Oncologists and pulmonologists involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

After completing this activity, the clinician should be able to:

• Analyze key safety and efficacy data for current and emerging frontline immunotherapy options in advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression levels ≥50%
• Assess the potential impact of emerging frontline immunotherapeutic approaches on treatment selection in patients with advanced NSCLC and high PD-L1 expression

Activity Description

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of regimens targeting the PD-1/PD-L1 axis. In this activity, Roy S. Herbst, MD, PhD and Sarah B. Goldberg, MD, MPH, share the latest data for current and emerging checkpoint inhibitor monotherapies in advanced NSCLC with high PD-L1 expression and provide expert guidance on optimizing frontline treatment selection.

Activity Chair

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology
Chief of Medical Oncology
Associate Cancer Center Director, Translational Research
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor of Medicine (Medical Oncology)
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Roy S. Herbst, MD, PhD, has affiliations with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa Therapeutics, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc, Symphogen, Takeda, Tesaro, Tocagen, WindMIL Therapeutics, Xencor, Inc. (Consulting); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company (Contracted Research); Junshi Pharmaceuticals (Board Member).

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Regeneron, Sanofi Genzyme (Consulting); AstraZeneca, Boehringer Ingelheim (ContractedResearch).

Planners and Managers
The PIM planners and managers have nothing to disclose. The RMEI Medical Education, LLC, planners and managers have nothing to disclose.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation

In order to claim MOC points, users must:

• Review and successfully complete the activity
• Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Jointly Provided By

Jointly provided by Postgraduate institute for Medicine and RMEI Medical Education, LLC.

Target Audience

Oncologists and pulmonologists involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

After completing this activity, the clinician should be able to:

• Analyze key safety and efficacy data for current and emerging frontline immunotherapy options in advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression levels ≥50%
• Assess the potential impact of emerging frontline immunotherapeutic approaches on treatment selection in patients with advanced NSCLC and high PD-L1 expression

Activity Description

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of regimens targeting the PD-1/PD-L1 axis. In this activity, Roy S. Herbst, MD, PhD and Sarah B. Goldberg, MD, MPH, share the latest data for current and emerging checkpoint inhibitor monotherapies in advanced NSCLC with high PD-L1 expression and provide expert guidance on optimizing frontline treatment selection.

Activity Chair

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology
Chief of Medical Oncology
Associate Cancer Center Director, Translational Research
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor of Medicine (Medical Oncology)
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Roy S. Herbst, MD, PhD, has affiliations with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa Therapeutics, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc, Symphogen, Takeda, Tesaro, Tocagen, WindMIL Therapeutics, Xencor, Inc. (Consulting); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company (Contracted Research); Junshi Pharmaceuticals (Board Member).

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Regeneron, Sanofi Genzyme (Consulting); AstraZeneca, Boehringer Ingelheim (ContractedResearch).

Planners and Managers
The PIM planners and managers have nothing to disclose. The RMEI Medical Education, LLC, planners and managers have nothing to disclose.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation

In order to claim MOC points, users must:

• Review and successfully complete the activity
• Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.